Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma

This study is testing a new first-line treatment combination for mantle cell lymphoma (a rare type of blood cancer) in patients who are healthy enough to eventually receive a stem cell transplant. The regimen combines a modified chemotherapy (VR-CAP) with a targeted drug called acalabrutinib, which blocks a protein that helps cancer cells grow. **You may be eligible if...** - You are 18–75 years old - You have newly diagnosed mantle cell lymphoma that has not been treated yet - Your lymphoma needs treatment and your doctor believes you could eventually qualify for a stem cell transplant - You have measurable disease on scans - Your blood counts and organ function are within acceptable ranges **You may NOT be eligible if...** - You have had prior treatment for mantle cell lymphoma - You are pregnant or breastfeeding - You have severe heart, liver, or kidney problems - You are taking blood thinners or medications that interact with the study drugs - You have active HIV or hepatitis B/C Talk to your doctor to see if this trial is right for you.